Lenus Stratify® selected for the Innovative Devices Access Pathway (IDAP) Pilot Programme
Lenus Health’s Stratify suite of AI models and insights app has been selected to participate in the IDAP pilot pathway. Established by the Department of Health and Social Care (DHSC) the pilot is an initiative to bring new technologies to the National Health Service (NHS) to help with medical needs that are not currently being met.
Lenus Stratify® is one of eight selected technologies from a range of medical devices sectors that will receive bespoke support from IDAP Partners including the Medicines and Healthcare products Regulatory Agency (MHRA), National Health Service England (NHSE), National Institute for Health and Care Excellence (NICE), Office of Life Sciences (OLS), Scottish Health Technologies Group (SHTG) and Health Technology Wales (HTW).
Lenus Stratify® provides accurate assessment of disease severity that has important implications for both treatment and prognosis. This software medical device uses machine learning models to generate risk prediction scores for patients with Chronic Obstructive Pulmonary Disease (COPD) identifying those at increased risk of hospital admission to help prioritise patients for treatment optimisation. The device has the potential to reorientate care provision from what is currently a largely reactive and expensive model to one focused on proactive intervention and delivery of preventative and personalised care.
COPD is a lung disease in which airways become narrow and damaged, leading to breathing difficulties. COPD tends to worsen over time including periods of acute events known as exacerbations leading to a significant increase in unscheduled care and hospital admissions.
The aim of IDAP is to enable and improve patient access to innovative and transformative medical devices by providing an integrated and enhanced regulatory and access pathway to developers. The pilot will test the main elements of the pathway and to provide informative learning and feedback that helps to build the future IDAP.